Tremfya tops Cosentyx in late-stage study

Johnson and  Johnsons Janssen has announced results from the Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya guselkumab compared with Cosentyx secukinumab in adults with moderate to severe plaque psoriasis. According to the data, published in The Lancet, a statistically significantly higher proportion of Tremfya patients achieved a PASI 90 response at Week 48 compared to those taking Cosentyx, and also demonstrate superiority of clinical response at Week 48 based on 90 Percent or better improvement in patients Psoriasis Area and Severity Index score compared to baseline. During the trial, patients were randomised to receive 100mg of Tremfya administered by subcutaneous injection at weeks zero and four, followed by every eight-week dosing; or 300mg of Cosentyx administered by two subcutaneous injections of 150mg at weeks zero, one, two, three and four followed by every four-week dosing.